[1] MOREAU P,SAN MIGUEL J,LUDWIG H,et al. Multiple myeloma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2013,24 Suppl 6:vi133-vi137. [2] NIJHOF I S,DONK N W C J,Zweegman S,et al.Curre nt and new therapeutic strategies for relapsed and refractory multiple myeloma:an update[J].Drugs,2018,78(1):19-37. [3] CHAPUY C I,NICHOLSON R T,AGUAD M D,et al.Resolving the daratumumab interference with blood compatibility testing[J].Transfusion,2015,55(6pt2):1545-1554. [4] CHAPUY C I,AGUAD M D,NICHOLSON R T,et al.International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing[J].Transfusion,2016,56(12):2964-2972. [5] 安万新,于卫建. 输血技术学(第二版) [M].北京:科学技术文献出版社,2010:269-276. [6] LANCMAN G,ARINSBURG S,JHANG J,et al.Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies[J].Front Immunol,2018,9:2616. [7] HUGAN S L,COOLING L,LARSSON V M.An evaluation of storage time for dithiothreitol-treated reagent cells[J].Transfusion,2017,57(10):2545-2546. [8] LALLY K,HAYES C,HIS R,et al.Extended Use of DTT-Treated Reagent Red Cells in the Era of anti-CD38 Therapy[C].AABB Annual Meeting, 2016,56(S4):136A. [9] LORENZEN H,LONE AKHTAR N,NIELSEN M,et al.Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing[J].Vox Sang,2018,113(7):686-693. [10] QUACH H,BENSON S,HAYSOM H,et al.Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma[J].Intern Med J,2018,48(2):210-220. |